Decreased number of CD19+CD24hiCD38hi regulatory B cells in Diabetic nephropathy. (August 2019)

• Record Type: Journal Article
• Authors: Li, Tao; Yu, Zhenxiang; Qu, Zhihui; Zhang, Nan; Crew, Rebecca; Jiang, Yanfang
• Is Part Of: Molecular immunology. Volume 112(2019:Aug.)
• Page Start: 233
• Page End: 239
• Publication Date: 2019-08
• Subjects: DN diabetic nephropathy -- DM diabetes Mellitus -- Bregs regulatory B cells -- BCR B cell receptor -- MZ marginal zone -- SLE systemic lupus erythematosus -- PBMCs peripheral blood mononuclear cells -- eGFR estimated glomerular filtration rate -- HC healthy controls; Regulatory B cells -- IL-10 -- Diabetic nephropathy -- eGFR -- Urinary protein; Immunochemistry -- Periodicals; Molecular biology -- Periodicals; Immunochemistry -- Periodicals; Allergy and Immunology -- Periodicals; Molecular Biology -- Periodicals; Immunochimie -- Périodiques; Biologie moléculaire -- Périodiques; Immunochemistry; Molecular biology; Periodicals; Electronic journals; 571.96
• DOI: 10.1016/j.molimm.2019.05.014
• Languages: English
• ISSNs: 0161-5890

Abstract

Highlights: CD19 + CD24 hi CD38 hi regulatory B cells may be involved in the pathogenesis of Diabetic nephropathy. Abnormal CD19 + CD24 hi CD38 hi regulatory B cells in patients with diabetic nephropathy can induce proteinuria and changes of glomerular rate. Hormone therapy can induce CD19 + CD24 hi CD38 hi regulatory B cells reconstruction and improve body injury in Diabetic nephropathy patients. Abstract: Background: Regulatory B cells participate in the pathogenesis of autoimmune disease. This study aimed to examine the putative contribution of regulatory B cells to the pathogenesis of DN. The number of circulating CD19 + CD24 hi CD38 hi B cells, CD19 + CD24 hi CD38 hi CD5 + B cells, and CD19 + CD24 hi CD38 hi IL-10 + B cells were significantly lower in DN patients (p < 0.05) than the control group. The number of circulating CD19 + CD24 hi CD38 hi B cells was positively correlated with the levels of eGFR and serum IL-10 levels, but negatively correlated with urinary protein levels in DN patients. Treatment significantly increased the number of CD19 + CD24 hi CD38 hi B cells, CD19 + CD24 hi CD38 hi CD5 + B cells, CD19 + CD24 hi CD38 hi IL-10 + B cells, and the levels of serum IL-10 (p < 0.05). We conclude that regulatory B cells may present new targets for intervention of DN.